GlobeNewswire: Mateon Therapeutics Contains the last 10 of 291 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T04:57:05ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/09/16/2094584/0/en/FDA-Granted-Pediatric-Disease-Designation-for-OXi-4503.html?f=22&fvtc=4&fvtv=7993FDA Granted Pediatric Disease Designation for OXi-45032020-09-16T13:00:00Z<![CDATA[-Treatment of acute myeloid leukemia (AML) due to genetic mutations that disproportionately affect pediatric patients -Treatment of acute myeloid leukemia (AML) due to genetic mutations that disproportionately affect pediatric patients]]>https://www.globenewswire.com/news-release/2020/09/14/2092847/0/en/Mateon-s-Global-Study-for-Artemisinin-Intervention-Against-COVID-19-Cleared-for-Patient-Enrollment-in-India.html?f=22&fvtc=4&fvtv=7993Mateon’s Global Study for Artemisinin Intervention Against COVID-19 Cleared for Patient Enrollment in India2020-09-14T11:00:00Z<![CDATA[AGOURA HILLS, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that its global study based on its ARTI-19 protocol for Artemisinin Intervention against COVID-19 has been cleared for patient enrollment in India.]]>https://www.globenewswire.com/news-release/2020/07/27/2067777/0/en/Mateon-Therapeutics-Closes-2-0-Million-Financing.html?f=22&fvtc=4&fvtv=7993Mateon Therapeutics Closes $2.0 Million Financing2020-07-27T11:00:00Z<![CDATA[AGOURA HILLS, Calif., July 27, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN) announced the closing of the 1st tranche of financing related to the Mateon operations and spinoff of its EdgePoint AI, Inc. (“EdgePoint”, a Delaware Corporation and a division of Mateon).]]>https://www.globenewswire.com/news-release/2020/07/20/2064256/0/en/Mateon-and-Asili-Research-Alliance-Enter-Into-Partnership-for-the-Development-of-Artemisinin-Against-Covid-19.html?f=22&fvtc=4&fvtv=7993Mateon and Asili Research Alliance Enter Into Partnership for the Development of Artemisinin Against Covid-192020-07-20T11:00:00Z<![CDATA[AGOURA HILLS, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today the launch of its global observational study called ARTI-19, for Artemisinin Intervention against COVID-19, in partnership with Asili Research Alliance (Asili) of Tanzania. ARTI19 is designed to rapidly establish the clinical efficacy of Artemisinin in mild and moderate COVID-19 patients. In-vitro, the medical grade version of the supplement has proven potency and safety similar to Remdesivir with an EC50 = 0.45 ug/ml and Safety Index = 140. If clinically proven effective, Artemisinin can provide relief to overwhelmed medical infrastructure and families affected by the pandemic in resource limited countries.]]>https://www.globenewswire.com/news-release/2020/07/13/2061112/0/en/Mateon-Therapeutics-to-fund-observational-studies-of-Artemisinin-in-developing-countries.html?f=22&fvtc=4&fvtv=7993Mateon Therapeutics to fund observational studies of Artemisinin in developing countries2020-07-13T11:00:00Z<![CDATA[AGOURA HILLS, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus. By collecting data from multiple clinical observational studies globally, the company expects to establish Artemisinin efficacy against COVID-19 as an affordable front-line treatment for this pandemic in low resources countries.]]>https://www.globenewswire.com/news-release/2020/06/24/2052621/0/en/Mateon-is-Selected-by-IBM-Watson-Health-for-the-Use-of-IBM-Clinical-Development-Solution-at-No-Cost-for-Phase-II-Clinical-Trial-of-OT-101-for-COVID-19.html?f=22&fvtc=4&fvtv=7993Mateon is Selected by IBM Watson Health for the Use of IBM Clinical Development Solution at No Cost for Phase II Clinical Trial of OT-101 for COVID-192020-06-24T11:00:00Z<![CDATA[Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s effort to help support and accelerate promising clinical COVID-19 candidates Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s effort to help support and accelerate promising clinical COVID-19 candidates]]>https://www.globenewswire.com/news-release/2020/06/23/2051868/0/en/Mateon-Therapeutics-Selects-IQVIA-for-its-Randomized-Controlled-Multi-Center-Clinical-Study-to-Test-OT-101-as-a-Treatment-for-COVID-19-Patients.html?f=22&fvtc=4&fvtv=7993Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients2020-06-23T11:00:00Z<![CDATA[AGOURA HILLS, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized, controlled, multi-center clinical study of OT-101.]]>https://www.globenewswire.com/news-release/2020/06/22/2051188/0/en/Mateon-and-GMP-Completed-Research-and-Service-Agreement.html?f=22&fvtc=4&fvtv=7993Mateon and GMP Completed Research and Service Agreement2020-06-22T12:00:00Z<![CDATA[Mateon and GMP to proceed to clinical development of OT-101 and Artemisin and other antisense drug candidates against COVID-19 Mateon and GMP to proceed to clinical development of OT-101 and Artemisin and other antisense drug candidates against COVID-19]]>https://www.globenewswire.com/news-release/2020/06/10/2046197/0/en/Mateon-Announces-Achievement-of-Milestone-Under-Licensing-of-OT-101-IL-2-Combination-to-Autotelic-BIO.html?f=22&fvtc=4&fvtv=7993Mateon Announces Achievement of Milestone Under Licensing of OT-101/IL-2 Combination to Autotelic BIO2020-06-10T12:00:00Z<![CDATA[AGOURA HILLS, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the fruition of its licensing of OT-101/IL-2 combination to Autotelic BIO based on an agreement entered into between Oncotelic and Autotelic BIO, a South Korean Company, during 2018.]]>https://www.globenewswire.com/news-release/2020/06/08/2044727/0/en/Mateon-Announces-an-Expansion-to-its-Pharmaceutical-Manufacturing-AI-Camera-Grid-by-Including-Contact-Tracing-to-Ensure-Worker-Safety.html?f=22&fvtc=4&fvtv=7993Mateon Announces an Expansion to its Pharmaceutical Manufacturing AI Camera Grid by Including Contact Tracing to Ensure Worker Safety2020-06-08T09:00:00Z<![CDATA[AGOURA HILLS, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) – Mateon announced that EdgePoint AI, a division within Mateon, announced its decision to expand its manufacturing AI vision camera grid to encompass a contact tracing application which will monitor the spread of COVID-19 indoors. TracePoint is an upgrade to the EdgePoint manufacturing grid to track contact between workers. The machine vision AI can help enforce social distancing and contact tracking. Mateon’s patented AI camera grid system is similar in scope and features to Amazon’s but at a fraction of the cost making it affordable for Contract Manufacturing Organizations (CMOs). Amazon’s vision grid is deployed in their retail chain, Amazon-Go, to track shoppers, and recently adapted to track contact between workers in warehouses.]]>